MorphoSys AG Company Profile (ETR:MOR)

About MorphoSys AG (ETR:MOR)

MorphoSys AG logoMorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation. Its product pipeline includes MOR208, a humanized monoclonal antibody that targets the antigen CD19, which is in Phase II clinical trials for the treatment of B cell malignancies; and MOR202, a human monoclonal HuCAL-antibody directed against CD38, which is in Phase I/IIa trials for the treatment of multiple myeloma and various leukemias. The company’s product pipeline also comprises MOR103, a human HuCAL-antibody directed against granulocyte-macrophage colony-stimulating factor that is in Phase II clinical trials for treating rheumatoid arthritis; and MOR209/ES414, a bi-specific anti-PSMA/anti-CD3 antibody against prostate cancer that is in Phase I clinical trials for the treatment of metastatic castration-resistant prostate cancer. In addition, its product pipeline includes MOR106, a human monoclonal IL-17C antibody, which is in Phase I clinical trials for the treatment of atopic dermatitis; and MOR107, a novel lanthipeptide that is in Phase I clinical trials for the treatment of fibrotic diseases. The company was founded in 1992 and is headquartered in Planegg, Germany.

Industry, Sector and Symbol: Average Prices:
  • 50 Day Moving Avg: €61.14
  • 200 Day Moving Avg: €58.04
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.000
Profitability:
  • Net Margins: -136.83%
  • Return on Equity: -16.24%
  • Return on Assets: -14.25%
 

Frequently Asked Questions for MorphoSys AG (ETR:MOR)

What is MorphoSys AG's stock symbol?

MorphoSys AG trades on the ETR under the ticker symbol "MOR."

Where is MorphoSys AG's stock going? Where will MorphoSys AG's stock price be in 2017?

7 brokers have issued twelve-month price targets for MorphoSys AG's stock. Their forecasts range from €55.00 to €90.00. On average, they expect MorphoSys AG's share price to reach €69.57 in the next twelve months. View Analyst Ratings for MorphoSys AG.

Who are some of MorphoSys AG's key competitors?

Who are MorphoSys AG's key executives?

MorphoSys AG's management team includes the folowing people:

  • Gerald Moeller, Chairman of the Supervisory Board
  • Simon E. Moroney Ph.D., Member of the Management Board, Chief Executive Officer
  • Jens Holstein, Chief Financial Officer, Member of the Management Board
  • Markus Enzelberger, Interim Chief Scientific Officer
  • Anke Linnartz, Vice President and Head of Corporate Communications and Investor Relations
  • Malte Peters, Chief Development Officer , Member of the Management Board
  • Marc Cluzel M.D., Ph.D., Member of the Supervisory Board
  • Karin Eastham CPA, Member of the Supervisory Board
  • Wendy Johnson, Member of the Supervisory Board
  • Klaus Kuehn, Member of the Supervisory Board


MarketBeat Community Rating for MorphoSys AG (ETR MOR)
Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  31 (Vote Outperform)
Underperform Votes:  21 (Vote Underperform)
Total Votes:  52
MarketBeat's community ratings are surveys of what our community members think about MorphoSys AG and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for MorphoSys AG (ETR:MOR) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Hold Ratings, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.57)
Consensus Price Target: €69.57

Analysts' Ratings History for MorphoSys AG (ETR:MOR)
Show:
DateFirmActionRatingPrice TargetDetails
8/16/2017Berenberg BankSet Price TargetBuy€68.00View Rating Details
8/7/2017Independent Research GmbHSet Price TargetBuy€77.00View Rating Details
8/7/2017Deutsche Bank AGSet Price TargetBuy€90.00View Rating Details
8/4/2017J P Morgan Chase & CoSet Price TargetNeutral€62.00View Rating Details
8/4/2017Goldman Sachs Group, Inc. (The)Set Price TargetNeutral€55.00View Rating Details
7/24/2017Commerzbank AgSet Price TargetBuy€76.00View Rating Details
7/14/2017HSBC Holdings plcSet Price TargetNeutral€59.00View Rating Details
(Data available from 8/21/2015 forward)

Earnings

Earnings History for MorphoSys AG (ETR:MOR)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for MorphoSys AG (ETR:MOR)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for MorphoSys AG (ETR:MOR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for MorphoSys AG (ETR:MOR)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for MorphoSys AG (ETR:MOR)
Latest Headlines for MorphoSys AG (ETR:MOR)
Source:
DateHeadline
americanbankingnews.com logoBerenberg Bank Reiterates €68.00 Price Target for MorphoSys AG (MOR)
www.americanbankingnews.com - August 21 at 11:02 PM
americanbankingnews.com logoMorphoSys AG (ETR:MOR) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - August 11 at 6:18 PM
finance.yahoo.com logoMorphoSys to Present at Upcoming Investor Conferences
finance.yahoo.com - August 11 at 6:36 AM
americanbankingnews.com logoMorphoSys AG (ETR:MOR) PT Set at €77.00 by Independent Research GmbH
www.americanbankingnews.com - August 7 at 10:14 AM
americanbankingnews.com logoMorphoSys AG (MOR) Given a €62.00 Price Target by J P Morgan Chase & Co Analysts
www.americanbankingnews.com - August 6 at 7:40 PM
seekingalpha.com logoMorphoSys AG 2017 Q2 - Results - Earnings Call Slides
seekingalpha.com - August 5 at 7:39 PM
finance.yahoo.com logoMorphoSys Reports Significant Progress in its Therapeutic Programs in Second Quarter of 2017
finance.yahoo.com - August 3 at 5:41 AM
americanbankingnews.com logoMorphoSys AG (MOR) PT Set at €77.00 by Independent Research GmbH
www.americanbankingnews.com - July 24 at 9:04 AM
finance.yahoo.com logoMorphoSys Announces that Its Partner, Bayer, Reports on Phase 2 Study of Investigational Anetumab Ravtansine in Second-Line Mesothelioma
finance.yahoo.com - July 22 at 6:33 AM
finance.yahoo.com logoAdhoc: MorphoSys Announces that Its Partner, Bayer, Reports on Phase 2 Study of Investigational Anetumab Ravtansine in Second-Line Mesothelioma
finance.yahoo.com - July 22 at 6:33 AM
americanbankingnews.com logoMorphoSys AG (MOR) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - July 17 at 12:52 PM
americanbankingnews.com logoMorphoSys AG (ETR:MOR) Receives "Neutral" Rating from J P Morgan Chase & Co
www.americanbankingnews.com - July 17 at 11:30 AM
americanbankingnews.com logoMorphoSys AG (ETR:MOR) Given a €77.00 Price Target at Independent Research GmbH
www.americanbankingnews.com - July 17 at 10:08 AM
rttnews.com logoFDA Oks Janssen' Tremfya To Treat Moderate To Severe Plaque Psoriasis
www.rttnews.com - July 15 at 6:34 AM
americanbankingnews.com logoHSBC Holdings plc Reiterates "€59.00" Price Target for MorphoSys AG (ETR:MOR)
www.americanbankingnews.com - July 14 at 10:46 AM
americanbankingnews.com logoMorphoSys AG (MOR) Given a €76.00 Price Target by Commerzbank Ag Analysts
www.americanbankingnews.com - July 14 at 8:22 AM
americanbankingnews.com logoMorphoSys AG (ETR:MOR) PT Set at €68.00 by Berenberg Bank
www.americanbankingnews.com - July 14 at 8:22 AM
finance.yahoo.com logoMorphoSys to Host Q2 2017 Conference Call on August 3, 2017
finance.yahoo.com - July 14 at 6:34 AM
finance.yahoo.com logoMorphoSys Announces that Its Licensee, Janssen, Has Received US FDA Approval for Tremfya(TM) (Guselkumab) for the Treatment of Moderate to Severe Plaque Psoriasis
finance.yahoo.com - July 14 at 6:34 AM
finanznachrichten.de logoMorphoSys AG: MorphoSys Celebrates 25th Anniversary
www.finanznachrichten.de - July 7 at 7:31 AM
finance.yahoo.com logoMorphoSys Celebrates 25th Anniversary
finance.yahoo.com - July 7 at 7:31 AM
reuters.com logoBRIEF-Aptevo Therapeutics' unit, CMC ICOS Biologics enter non-exclusive amended and restated commercial supply agreement
www.reuters.com - June 22 at 8:33 AM
finance.yahoo.com logoDistrict Court Grants MorphoSys's Request to Add Second Patent in Lawsuit with Janssen Biotech and Genmab
finance.yahoo.com - June 20 at 8:36 AM
finance.yahoo.com logoMorphoSys's Subsidiary Lanthio Pharma Initiates First-in-Human Clinical Study with Lanthipeptide MOR107
finance.yahoo.com - June 20 at 8:36 AM
finance.yahoo.com logoInvitation to Year-End Results 2016 Conference Call
finance.yahoo.com - June 20 at 8:36 AM
finance.yahoo.com logoMorphoSys Announces that its Licensee Janssen has Reported New Data from Two Phase 3 Studies of Guselkumab in Plaque Psoriasis
finance.yahoo.com - June 20 at 8:36 AM
finance.yahoo.com logoMorphoSys Partner to Start New Phase 3 Clinical Trials with Gantenerumab in Alzheimer's Disease
finance.yahoo.com - June 20 at 8:36 AM
finance.yahoo.com logoMorphoSys AG Presents Strong Results for Fiscal Year 2016
finance.yahoo.com - June 20 at 8:36 AM
finance.yahoo.com logoMorphoSys's CSO Marlies Sproll Takes Temporary Leave, Markus Enzelberger to Serve as Interim CSO
finance.yahoo.com - June 20 at 8:36 AM
finance.yahoo.com logoMorphoSys Nominates New Candidate for Supervisory Board
finance.yahoo.com - June 20 at 8:36 AM
finance.yahoo.com logoMorphoSys to Present at Upcoming Conferences
finance.yahoo.com - June 20 at 8:36 AM
finance.yahoo.com logoMorphoSys to Host Q1 2017 Conference Call on May 3, 2017
finance.yahoo.com - June 20 at 8:36 AM
finance.yahoo.com logoMorphoSys AG Reports Solid First Quarter 2017
finance.yahoo.com - June 20 at 8:36 AM
finance.yahoo.com logoInvestor Network: MorphoSys AG to Host Earnings Call
finance.yahoo.com - June 20 at 8:36 AM
finance.yahoo.com logoMorphoSys AG Reports Outcome of Annual General Meeting 2017
finance.yahoo.com - June 20 at 8:36 AM
finance.yahoo.com logoMorphoSys Presents First Safety and Efficacy Data of MOR208 in Combination with Lenalidomide from a Phase 2 Study in DLBCL
finance.yahoo.com - June 20 at 8:36 AM
finance.yahoo.com logoMorphoSys Presents Updated Clinical Data for Anti-CD38 Antibody MOR202 in Multiple Myeloma at ASCO 2017
finance.yahoo.com - June 20 at 8:36 AM
americanbankingnews.com logoMorphoSys AG (MOR) Given a €76.00 Price Target at Commerzbank Ag
www.americanbankingnews.com - June 11 at 1:26 PM
americanbankingnews.com logoMorphoSys AG (MOR) PT Set at €55.00 by Goldman Sachs Group Inc
www.americanbankingnews.com - June 6 at 11:44 AM
americanbankingnews.com logoCommerzbank Ag Analysts Give MorphoSys AG (MOR) a €76.00 Price Target
www.americanbankingnews.com - May 30 at 7:32 AM
americanbankingnews.com logoIndependent Research GmbH Reiterates €77.00 Price Target for MorphoSys AG (MOR)
www.americanbankingnews.com - May 29 at 8:10 AM
americanbankingnews.com logoMorphoSys AG (MOR) PT Set at €68.00 by Berenberg Bank
www.americanbankingnews.com - May 25 at 9:32 AM

Social

Social activity is not available for this stock.
This page was last updated on 8/21/2017 by MarketBeat.com Staff